Adnan Ajmal1, Hadine Joffe2, Lisa B Nachtigall3. 1. Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 2. Center for Women's Mental Health, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 3. Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address: lnachtigall@partners.org.
Abstract
BACKGROUND: Psychotropic medications, particularly select antipsychotics, are a common cause of drug-induced hyperprolactinemia. As high prolactin may be associated with hypogonadism, reproductive dysfunction, and bone loss, it is important to recognize this condition and understand its management. OBJECTIVE: The aim of this review is to evaluate the causes, signs, and symptoms associated with hyperprolactinemia, to describe mechanisms through which psychotropic medications elevate prolactin, and to suggest an evidence-based management approach for patients with psychotropic drug-induced hyperprolactinemia. METHODS: A PubMed/MEDLINE search was conducted on the topic of psychotropic agents as a cause of hyperprolactinemia. The material with most relevance to current psychiatric practice and of highest level of evidence was included in this review. CONCLUSION: Hyperprolactinemia should be evaluated in adult patients receiving psychotropic agents if signs and symptoms associated with hyperprolactinemia are present. It is also important to exclude pituitary and hypothalamic disease by magnetic resonance imaging if hyperprolactinemia is not definitely caused by psychotropic medications. As bone loss may occur because of hyperprolactinemia-mediated hypogonadism, bone mineral density (BMD) should be evaluated in patients with persistent high prolactin and reproductive dysfunction. Aripiprazole or other prolactin-sparing atypical antipsychotics may be alternatives or aripiprazole can be considered as adjunctive therapy in select cases of psychotropic-induced hyperprolactinemia.
BACKGROUND: Psychotropic medications, particularly select antipsychotics, are a common cause of drug-induced hyperprolactinemia. As high prolactin may be associated with hypogonadism, reproductive dysfunction, and bone loss, it is important to recognize this condition and understand its management. OBJECTIVE: The aim of this review is to evaluate the causes, signs, and symptoms associated with hyperprolactinemia, to describe mechanisms through which psychotropic medications elevate prolactin, and to suggest an evidence-based management approach for patients with psychotropic drug-induced hyperprolactinemia. METHODS: A PubMed/MEDLINE search was conducted on the topic of psychotropic agents as a cause of hyperprolactinemia. The material with most relevance to current psychiatric practice and of highest level of evidence was included in this review. CONCLUSION:Hyperprolactinemia should be evaluated in adult patients receiving psychotropic agents if signs and symptoms associated with hyperprolactinemia are present. It is also important to exclude pituitary and hypothalamic disease by magnetic resonance imaging if hyperprolactinemia is not definitely caused by psychotropic medications. As bone loss may occur because of hyperprolactinemia-mediated hypogonadism, bone mineral density (BMD) should be evaluated in patients with persistent high prolactin and reproductive dysfunction. Aripiprazole or other prolactin-sparing atypical antipsychotics may be alternatives or aripiprazole can be considered as adjunctive therapy in select cases of psychotropic-induced hyperprolactinemia.
Authors: Deanna L Kelly; Megan M Powell; Heidi J Wehring; MacKenzie A Sayer; Ann Marie Kearns; Ann L Hackman; Robert W Buchanan; Rebecca B Nichols; Heather A Adams; Charles M Richardson; Gopal Vyas; Robert P McMahon; Amber K Earl; Kelli M Sullivan; Fang Liu; Sarah E Luttrell; Faith B Dickerson; Stephanie M Feldman; Supriya Narang; Maju M Koola; Peter F Buckley; Jill A RachBeisel; Joseph P McEvoy Journal: J Clin Psychopharmacol Date: 2018-08 Impact factor: 3.153
Authors: Lucia Margari; Emilia Matera; Maria G Petruzzelli; Marta Simone; Anna L Lamanna; Adriana Pastore; Vincenzo O Palmieri; Francesco Margari Journal: Int Clin Psychopharmacol Date: 2015-03 Impact factor: 1.659
Authors: Dhanya Raveendranthan; Naren P Rao; Mukund G Rao; Ajish G Mangot; Shivaram Varambally; Muralidharan Kesavan; Ganesan Venkatasubramanian; Bangalore N Gangadhar Journal: Indian J Psychol Med Date: 2018 Jan-Feb
Authors: Arundhati Undurti; Elizabeth A Colasurdo; Carl L Sikkema; Jaclyn S Schultz; Elaine R Peskind; Kathleen F Pagulayan; Charles W Wilkinson Journal: Front Neurol Date: 2018-02-19 Impact factor: 4.003
Authors: William A Bauman; Michael F La Fountaine; Christopher M Cirnigliaro; Steven C Kirshblum; Ann M Spungen Journal: Spinal Cord Date: 2017-11-15 Impact factor: 2.772